ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Guideline-concordant therapy for community-onset pneumonia considering risk factors for drug-resistant pathogens: a propensity score-matched study.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGuideline-concordant therapy (GCT) has been associated with improved outcomes in patients with community-onset pneumonia. However, the impact of GCT remains unclear when the risk of drug-resistant pathogens, such as methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa, is considered.
methodsWe retrospectively evaluated the safety and efficacy of GCT for hospitalised adult patients with community-onset pneumonia at a 270-bed community hospital in Yamanashi, Japan, between January 1, 2020, and May 31, 2025. GCT was defined according to adult pneumonia guidelines issued by the Japanese Respiratory Society 2024 (JRS 2024). Patients were matched one-to-one using propensity score matching. The primary endpoint was 28-day mortality. The study was approved by the Yamanashi Red Cross Hospital Ethics Committee (approval number: 7 - 2, approval date: 01/September/2025).
resultsOf the 540 eligible patients, 380 were included in the matched analysis. The Kaplan-Meier curve for 28-day mortality showed no statistically significant difference between the GCT group and the non-GCT group (hazard ratio, 1.02; 95% CI, 0.82-1.27, P = 0.94).
conclusionIn this single-center observational cohort of patients with community-onset pneumonia, GCT according to the JRS 2024 guideline was not associated with lower 28-day mortality than non-GCT. These findings should be interpreted cautiously in light of the observational study design, the clinical heterogeneity of the cohort, and the potential for residual confounding. Further studies are needed to evaluate the effectiveness of JRS 2024-based treatment strategies in broader clinical settings.
Indexed as
Identifiers
42640391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.